Sign up USA
Proactive Investors - Run By Investors For Investors

Regeneron higher after key drugs help deliver market-beating fourth quarter

The company’s key drugs – Praluent and Dupixent, and sales of Eyelea in the US – helped to lift the numbers for the quarter
eye drops
The company is anticipating additional pipeline progress in 2018

Regeneron Pharmaceuticals Inc.(NASDAQ:REGN) saw its shares gain traction in early trade after the company recorded fourth-quarter numbers that beat market expectations.

The company’s key drugs – Praluent and Dupixent, and sales of Eyelea in the US – helped to lift the numbers for the quarter.

Quarterly and 2017 hit by new tax reform

In a statement, the company said earnings dropped to US$174mln or US$1.50 per share, from the US$253mln, or US$2.19 per share a year ago.

Adjusted earnings-per-share came in at US$5.23, against market expectations for US$4.48.

During the period, revenue rose to US$1.58bn from US$1.23bn, and well above market expectations for US$1.50bn.

Regeneron recorded a US$326.2mln charge related to the new tax legislation, which hit the fourth quarter and the full year 2017 effective tax rates.

Leonard S. Schleifer, president and CEO said: "We are anticipating additional pipeline progress in 2018, including regulatory decisions for dupilumab in uncontrolled asthma and cemiplimab in advanced cutaneous squamous cell carcinoma, cardiovascular outcomes data for Praluent, as well as Phase 3 data for EYLEA in diabetic retinopathy."

Its shares were up 2.35% at US$342.54.

View full REGN profile View Profile

Regeneron Pharmaceuticals Timeline

Related Articles

April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
July 30 2018
Life science generally is developing at an incredible speed, says Joe Anderson

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use